Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Retained Earnings (2016 - 2025)

Abeona Therapeutics has reported Retained Earnings over the past 15 years, most recently at $138000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at $138000.0 for Q4 2025, up 1625.0% from a year ago — trailing twelve months through Dec 2025 was $138000.0 (up 1625.0% YoY), and the annual figure for FY2025 was $138000.0, up 1625.0%.
  • Retained Earnings for Q4 2025 was $138000.0 at Abeona Therapeutics, up from $10000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for ABEO hit a ceiling of $688.2 million in Q3 2022 and a floor of -$804.0 million in Q3 2024.
  • Median Retained Earnings over the past 5 years was -$293.4 million (2021), compared with a mean of -$282.8 million.
  • Biggest five-year swings in Retained Earnings: surged 7646933.33% in 2022 and later plummeted 2348043.33% in 2023.
  • Abeona Therapeutics' Retained Earnings stood at -$655.6 million in 2021, then decreased by 6.05% to -$695.3 million in 2022, then dropped by 7.79% to -$749.5 million in 2023, then soared by 100.0% to $8000.0 in 2024, then surged by 1625.0% to $138000.0 in 2025.
  • The last three reported values for Retained Earnings were $138000.0 (Q4 2025), $10000.0 (Q3 2025), and -$45000.0 (Q2 2025) per Business Quant data.